Alchemab Therapeutics
Develops antibody therapeutics using patient immune-response data to identify protective antibodies for hard-to-treat diseases.
Overview
Alchemab Therapeutics is a life sciences company focused on discovering and developing antibody-based therapeutics. Its work centers on analyzing immune responses to identify naturally protective antibodies that could inform treatments for serious diseases. The company targets pharmaceutical and healthcare markets seeking novel therapeutic candidates, with differentiation tied to its immune-data-driven discovery approach. It raised $34 million in a Series A round in July 2026, described as €29.3 million and the British Business Bank’s largest life sciences investment to date.
Funding History
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
Frequently Asked Questions
- How much has Alchemab Therapeutics raised in total?
- Alchemab Therapeutics has raised a total of $34M across 1 funding round.
- Who are Alchemab Therapeutics's investors?
- Alchemab Therapeutics's investors include the British Business Bank.
- What does Alchemab Therapeutics do?
- Alchemab Therapeutics is a life sciences company focused on discovering and developing antibody-based therapeutics. Its work centers on analyzing immune responses to identify naturally protective antibodies that could inform treatments for serious diseases. The company targets pharmaceutical and healthcare markets seeking novel therapeutic candidates, with differentiation tied to its immune-data-driven discovery approach. It raised $34 million in a Series A round in July 2026, described as €29.3 million and the British Business Bank’s largest life sciences investment to date.
- Where is Alchemab Therapeutics headquartered?
- Alchemab Therapeutics is headquartered in Cambridge, United Kingdom.
Related Insights
A comprehensive analysis of Theo's funding history, investors, competitive position, and growth trajectory in the AI Fintech space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive geographic analysis of AI venture funding in 2026. San Francisco dominates with $31.4B across 32 companies, but Europe is breaking out with $7.1B in Paris, London, Amsterdam, and Stockholm. We map every city, sector specialization, and emerging hub.